Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effectiveness of SARS-CoV-2 vaccination in patients with rheumatoid arthritis (RA) on DMARDs: as determined by antibody and T cell responses
Benazir Saleem, Rebecca L. Ross, Lesley-Anne Bissell, et al.
RMD Open (2022) Vol. 8, Iss. 1, pp. e002050-e002050
Open Access | Times Cited: 23

Showing 23 citing articles:

Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study
Md Yuzaiful Md Yusof, Jack Arnold, Benazir Saleem, et al.
The Lancet Rheumatology (2023) Vol. 5, Iss. 2, pp. e88-e98
Open Access | Times Cited: 43
Impact of Immunomodulatory Therapy on COVID-19 Vaccine Response in Patients with Autoimmune Inflammatory Rheumatic Diseases
Ruth Xian Lynn Yap, Yi Wye Lai, Chang Wei, et al.
Vaccines (2024) Vol. 12, Iss. 3, pp. 274-274
Open Access | Times Cited: 6
Efficacy and safety of mRNA and AstraZeneca COVID-19 vaccines in patients with autoimmune rheumatic diseases: A systematic review
Anwar I. Joudeh, Abdu Qaid Lutf, Salah Mahdi, et al.
Vaccine (2023) Vol. 41, Iss. 26, pp. 3801-3812
Open Access | Times Cited: 12
Rheumatoid Arthritis and COVID-19 at the Intersection of Immunology and Infectious Diseases: A Related PRISMA Systematic Literature Review
Andreea-Iulia Vlădulescu-Trandafir, Violeta‐Claudia Bojincă, Constantin Munteanu, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 20, pp. 11149-11149
Open Access | Times Cited: 4
Outcomes of COVID-19 Omicron variant in patients with rheumatoid arthritis: a nationwide Greek cohort study
Vasiliki-Kalliopi Bournia, G. Fragoulis, Panagiota Mitrou, et al.
Lara D. Veeken (2023) Vol. 63, Iss. 4, pp. 1130-1138
Open Access | Times Cited: 9
Differential cellular and humoral immune responses in immunocompromised individuals following multiple SARS-CoV-2 vaccinations
Rhys T Meredith, Max D Bermingham, Kirsten Bentley, et al.
Frontiers in Cellular and Infection Microbiology (2023) Vol. 13
Open Access | Times Cited: 7
Diminished responses to mRNA-based SARS-CoV-2 vaccines in individuals with rheumatoid arthritis on immune-modifying therapies
Samuel D. Klebanoff, Lauren B. Rodda, Chihiro Morishima, et al.
JCI Insight (2023) Vol. 8, Iss. 15
Open Access | Times Cited: 6
TNF inhibitors significantly attenuate the humoral immune response to COVID-19 vaccination in patients with rheumatoid arthritis
Arne Schäfer, Magdolna Szilvia Kovacs, Anna Eder, et al.
Rheumatology Advances in Practice (2023) Vol. 7, Iss. 2
Open Access | Times Cited: 6
Glucocorticoid use as a cause of non-cellular immune response to SARS-Cov2 Spike in patients with immune system diseases
Yves Renaudineau, L. Sailler, Florence Abravanel, et al.
Journal of Autoimmunity (2022) Vol. 133, pp. 102912-102912
Open Access | Times Cited: 9
Persistence of SARS-CoV-2 neutralizing antibodies and anti-Omicron IgG induced by BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic disease: an explanatory study in Japan
Yuta Yamaguchi, Shinichiro Nameki, Yasuhiro Kato, et al.
The Lancet Regional Health - Western Pacific (2022) Vol. 32, pp. 100661-100661
Open Access | Times Cited: 7
Managing Patients with Immune-Mediated Inflammatory Diseases on Disease-Modifying Antirheumatic Drug Therapy in a COVID-19 Endemic World: A Narrative Review and Expert Insights
Kok Ooi Kong, Pinyo Rattanaumpawan, Nguyen Chau Tuan, et al.
(2024)
Open Access | Times Cited: 1
COVID-19 vaccine immunogenicity in 16 patients with autoimmune systemic diseases. Lack of both humoral and cellular response to booster dose and ongoing disease modifying therapies
Laura Gragnani, Marcella Visentini, Serena Lorini, et al.
Journal of Translational Autoimmunity (2022) Vol. 5, pp. 100164-100164
Open Access | Times Cited: 6
Rheumatoid arthritis and older age are associated with lower humoral and cellular immune response to primary series COVID-19 mRNA vaccine
Holly Dudley, Megan L. O’Mara, Ann Auma, et al.
Vaccine (2023) Vol. 41, Iss. 41, pp. 6112-6119
Open Access | Times Cited: 3
COVID-19 Vaccination and Immunosuppressive Therapy in Immune-Mediated Inflammatory Diseases
José M. Serra López-Matencio, Esther F. Vicente‐Rabaneda, Estefanía Alañón, et al.
Vaccines (2023) Vol. 11, Iss. 12, pp. 1813-1813
Open Access | Times Cited: 3
Impact of different classes of immune-modulating treatments on B cell-related and T cell-related immune response before and after COVID-19 booster vaccination in patients with immune-mediated diseases and primary immunodeficiency: a cohort study
Michaela Koehm, Maximilian Klippstein, Stephanie Dauth, et al.
RMD Open (2023) Vol. 9, Iss. 3, pp. e003094-e003094
Open Access | Times Cited: 2
Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RA
Kristin Schmiedeberg, Irène A. Abela, Natalia Pikor, et al.
RMD Open (2022) Vol. 8, Iss. 2, pp. e002575-e002575
Open Access | Times Cited: 3
Diminished responses to mRNA-based SARS-CoV-2 vaccines in individuals with rheumatoid arthritis on immune modifying therapies
Samuel D. Klebanoff, Lauren B. Rodda, Chihiro Morishima, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1
The burden of COVID-19 in a heterogeneous population of immunocompromised patients – realities of the postpandemic
С. Н. Авдеев, Vladimir Chulanov, Е.I. Alexeeva, et al.
Terapevticheskii arkhiv (2023) Vol. 95, Iss. 8, pp. 722-729
Open Access | Times Cited: 1
Determination of the factors associated with antigen-specific CD4+ T-cell responses to BNT162b2 in patients with rheumatoid arthritis
Fumiaki Sagawa, Hisakata Yamada, Masahiro Ayano, et al.
RMD Open (2024) Vol. 10, Iss. 1, pp. e003693-e003693
Open Access
Effectiveness and Safety of the COVID-19 Vaccine in Patients with Rheumatoid Arthritis in a Real-World Setting
María Torres-Rufas, Esther F. Vicente‐Rabaneda, Laura Cardeñoso, et al.
Vaccines (2024) Vol. 12, Iss. 6, pp. 672-672
Open Access
Characterization of genetic landscape and novel inflammatory biomarkers in patients with adult‐onset Still's disease
Joanne Topping, Leon Chang, Fatima Nadat, et al.
Arthritis & Rheumatology (2024)
Open Access
Immunogenicity of Vaccines Against SARS-CoV-2 In Patients With Rheumatic Diseases
BS Belov, N. V. Muravyevа, A. N. Kulikov
Antibiot Khimioter = Antibiotics and Chemotherapy (2022) Vol. 67, Iss. 5-6, pp. 70-80
Open Access | Times Cited: 1
Time Course of Antispike Antibody Titer after Administration of BNT162b2 mRNA COVID-19 Vaccine in a Patient with Rheumatoid Arthritis on Methotrexate
S Shinohara, Yasuhiro Hirose
Case Reports in Rheumatology (2023) Vol. 2023, pp. 1-5
Open Access
Page 1

Scroll to top